Apical Sodium-Dependent Transporter Inhibitors in Primary Biliary Cholangitis and Primary Sclerosing Cholangitis

Vinod S Hegade; David E J Jones; Gideon M Hirschfield

doi:10.1159/000450988

Apical Sodium-Dependent Transporter Inhibitors in Primary Biliary Cholangitis and Primary Sclerosing Cholangitis

Vinod S Hegade, David E J Jones, Gideon M Hirschfield

Immunology and Immunotherapy

Research output: Contribution to journal › Article › peer-review

14 Citations (Scopus)

273 Downloads (Pure)

Abstract

Bile acids (BAs) have gained mainstream attention since the discovery of their key role as signalling molecules in health and disease. The apical sodium-dependent transporter (ASBT) protein located in the terminal ileum plays an important physiological role in the enterohepatic circulation of BAs and therefore essential for the BA homeostasis. Primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC), the 2 most common cholestatic liver diseases are characterised by altered BA flow and BA composition, which contribute to disease progression and symptom (pruritus) development. Therefore, changing the circulating BA pool in patients with PBC and PSC may have therapeutic implications. To this end, pharmacological inhibition of ASBT is fast emerging as an interesting target. In this review, we discuss the recent evidence for potential therapeutic use of ASBT inhibitors to treat PBC and PSC patients.

Original language	English
Pages (from-to)	267-274
Number of pages	8
Journal	Digestive Diseases
Volume	35
Issue number	3
Early online date	1 Mar 2017
DOIs	https://doi.org/10.1159/000450988
Publication status	E-pub ahead of print - 1 Mar 2017

Keywords

Animals
Cholangitis, Sclerosing
Humans
Liver Cirrhosis, Biliary
Membrane Transport Proteins
Models, Biological
Peptides
Journal Article
Review

Access to Document

10.1159/000450988Licence: None: All rights reserved

ASBTinhibitors_PBC_PSC_2016_Final
Checked for eligibility: 03/08/2017 This is the peer-reviewed but unedited manuscript version of the following article: Hegade, Vinod S., David EJ Jones, and Gideon M. Hirschfield. "Apical Sodium-Dependent Transporter Inhibitors in Primary Biliary Cholangitis and Primary Sclerosing Cholangitis." Digestive Diseases 35.3 (2017): 267-274. The final, published version is available at https://www.karger.com/Article/Abstract/450988
Accepted author manuscript, 602 KB

Cite this

@article{a801de52744d4ecbb3fa9a204634e794,

title = "Apical Sodium-Dependent Transporter Inhibitors in Primary Biliary Cholangitis and Primary Sclerosing Cholangitis",

abstract = "Bile acids (BAs) have gained mainstream attention since the discovery of their key role as signalling molecules in health and disease. The apical sodium-dependent transporter (ASBT) protein located in the terminal ileum plays an important physiological role in the enterohepatic circulation of BAs and therefore essential for the BA homeostasis. Primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC), the 2 most common cholestatic liver diseases are characterised by altered BA flow and BA composition, which contribute to disease progression and symptom (pruritus) development. Therefore, changing the circulating BA pool in patients with PBC and PSC may have therapeutic implications. To this end, pharmacological inhibition of ASBT is fast emerging as an interesting target. In this review, we discuss the recent evidence for potential therapeutic use of ASBT inhibitors to treat PBC and PSC patients.",

keywords = "Animals, Cholangitis, Sclerosing, Humans, Liver Cirrhosis, Biliary, Membrane Transport Proteins, Models, Biological, Peptides, Journal Article, Review",

author = "Hegade, {Vinod S} and Jones, {David E J} and Hirschfield, {Gideon M}",

note = "{\textcopyright} 2017 S. Karger AG, Basel.",

year = "2017",

month = mar,

day = "1",

doi = "10.1159/000450988",

language = "English",

volume = "35",

pages = "267--274",

journal = "Digestive Diseases",

issn = "0257-2753",

publisher = "Karger",

number = "3",

}

TY - JOUR

T1 - Apical Sodium-Dependent Transporter Inhibitors in Primary Biliary Cholangitis and Primary Sclerosing Cholangitis

AU - Hegade, Vinod S

AU - Jones, David E J

AU - Hirschfield, Gideon M

PY - 2017/3/1

Y1 - 2017/3/1

N2 - Bile acids (BAs) have gained mainstream attention since the discovery of their key role as signalling molecules in health and disease. The apical sodium-dependent transporter (ASBT) protein located in the terminal ileum plays an important physiological role in the enterohepatic circulation of BAs and therefore essential for the BA homeostasis. Primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC), the 2 most common cholestatic liver diseases are characterised by altered BA flow and BA composition, which contribute to disease progression and symptom (pruritus) development. Therefore, changing the circulating BA pool in patients with PBC and PSC may have therapeutic implications. To this end, pharmacological inhibition of ASBT is fast emerging as an interesting target. In this review, we discuss the recent evidence for potential therapeutic use of ASBT inhibitors to treat PBC and PSC patients.

AB - Bile acids (BAs) have gained mainstream attention since the discovery of their key role as signalling molecules in health and disease. The apical sodium-dependent transporter (ASBT) protein located in the terminal ileum plays an important physiological role in the enterohepatic circulation of BAs and therefore essential for the BA homeostasis. Primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC), the 2 most common cholestatic liver diseases are characterised by altered BA flow and BA composition, which contribute to disease progression and symptom (pruritus) development. Therefore, changing the circulating BA pool in patients with PBC and PSC may have therapeutic implications. To this end, pharmacological inhibition of ASBT is fast emerging as an interesting target. In this review, we discuss the recent evidence for potential therapeutic use of ASBT inhibitors to treat PBC and PSC patients.

KW - Animals

KW - Cholangitis, Sclerosing

KW - Humans

KW - Liver Cirrhosis, Biliary

KW - Membrane Transport Proteins

KW - Models, Biological

KW - Peptides

KW - Journal Article

KW - Review

U2 - 10.1159/000450988

DO - 10.1159/000450988

M3 - Article

C2 - 28249258

SN - 0257-2753

VL - 35

SP - 267

EP - 274

JO - Digestive Diseases

JF - Digestive Diseases

IS - 3

ER -

Apical Sodium-Dependent Transporter Inhibitors in Primary Biliary Cholangitis and Primary Sclerosing Cholangitis

Abstract

Keywords

Access to Document

Fingerprint

Cite this